CM
TARO

Crystalline Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Crystalline Management’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,116
Closed -$297K – 116
2023
Q4 		$297K Buy
+7,116
New +$262K 0.38% 52

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Crystalline Management's TARO Position: Q1 2024 in Review

Crystalline Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2024, closing a stake of 7,116 shares — an estimated $297K sold.

Crystalline Management first reported a position in TARO in Q4 2023 and held it in 1 quarter. The position peaked at $297K in Q4 2023. 94 funds tracked by Wall St. Rank hold TARO as of Q1 2024.

  • Crystalline Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2024 after selling out during the quarter.
  • Crystalline Management sold 7,116 Taro Pharmaceutical Industries Ltd. shares in Q1 2024, an estimated $297K.
  • Crystalline Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2023 and held it in 1 quarter.
  • Crystalline Management's Taro Pharmaceutical Industries Ltd. position peaked at $297K in Q4 2023.
  • 94 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2024.

Based on Crystalline Management's 13F filing for Q1 2024, filed 10 May 2024.